Article
CLR 131 Elicits Clinically Meaningful Responses in Triple-Class Refractory Myeloma
Rating:
0.0
Views:
97
Likes:
1
Library:
1
The first-in-class radioiodinated phospholipid drug conjugate CLR 131 elicited a clinically meaningful overall response rate of 40% in patients with triple-class refractory multiple myeloma who received a total administered dose of 60 mCi or greater.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value